ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Esperion Therapeutics Inc

Esperion Therapeutics Inc (ESPR)

2.63
0.01
( 0.38% )
Updated: 13:38:06

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

ESPR News

Official News Only

ESPR Discussion

View Posts
FACT-MASTER FACT-MASTER 2 days ago
ESPR: https://finance.yahoo.com/news/esperion-announces-data-clear-outcomes-200000681.html
👍️0
FACT-MASTER FACT-MASTER 2 days ago
ESPR: https://finance.yahoo.com/news/u-fda-approves-broad-labels-222600152.html
👍️0
FACT-MASTER FACT-MASTER 2 days ago
ESPR: https://finance.yahoo.com/news/chmp-issues-positive-opinions-both-150400959.html
👍️0
glenn1919 glenn1919 5 days ago
ESPR.....................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
jerrybrockman jerrybrockman 6 days ago
I don’t think many realize that the FDA label change issued today is massive for exponential sales
👍️0
FACT-MASTER FACT-MASTER 1 month ago
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Esperion Therapeutics (ESPR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus Estimate

This biopharmaceutical company is expected to post quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of +30.3%.

Revenues are expected to be $26.84 million, up 42.6% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 10.09% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Esperion Therapeutics?

For Esperion Therapeutics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +24.53%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination indicates that Esperion Therapeutics will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Esperion Therapeutics would post a loss of $0.42 per share when it actually produced a loss of $0.37, delivering a surprise of +11.90%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Esperion Therapeutics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
👍️0
FACT-MASTER FACT-MASTER 1 month ago
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27

https://finance.yahoo.com/news/esperion-report-fourth-quarter-full-130000274.html
👍️0
FACT-MASTER FACT-MASTER 2 months ago
ESPR: Forms SC 13G/A - recently filed

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318050067&type=PDF&symbol=ESPR&cdn=6fc63478d06f4b5a4584535edb5d9b63&companyName=Esperion+Therapeutics+Inc.&formType=SC+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2024-02-09

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318003668&type=PDF&symbol=ESPR&cdn=c0b4a9667e272499e55136677cb46f76&companyName=Esperion+Therapeutics+Inc.&formType=SC+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2024-01-24

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318003572&type=PDF&symbol=ESPR&cdn=2746258dcda88a9a154e6a5247a1cce6&companyName=Esperion+Therapeutics+Inc.&formType=SC+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2024-01-24
👍️0
FACT-MASTER FACT-MASTER 2 months ago
ESPR: Promotional Schedule - 2024

https://finance.yahoo.com/news/rfk-esperion-therapeutics-announce-2024-190000171.html

NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024

CONCORD, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- RFK Racing and Esperion Therapeutics have announced the promotional schedule for the 2024 season, highlighted by a four-race slate, and numerous accompanying campaigns and initiatives, all driving awareness of its two brands – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid) used for adults on a statin to reduce LDL-cholesterol.

Esperion’s season debut comes in the first race at Richmond this spring (March 31) on the No. 17 of Chris Buescher. Brad Keselowski’s debut with the brand comes at the All-Star Race at North Wilkesboro (May 19). Remaining races include Pocono on the No. 6 (July 14), and the fall Talladega event on the No. 17 (Oct. 6).

RFK and Esperion will collaborate to wave the red flag for uncontrolled cholesterol by promoting a myriad of campaigns, including National Wear Red Day, American Heart Month, Stress Awareness Month, Women’s Health Awareness Month, Men’s Health Awareness Month, a Wellness Walk, Cholesterol Education Month, World Heart Day, National Health Education Week, and Family Health History Day.

In addition, Buescher will attend the annual American College of Cardiology (ACC) session on behalf of Esperion, in April in Atlanta. RFK will also promote the brand’s NASCAR Digital Media buy, which will include various graphics packages on NASCAR.com, as well as an in-car camera on the No. 6 for the second Talladega race.

Esperion is also partnering with Pocono Raceway to host a Wellness Walk the Saturday morning of its race weekend, which will invite fans in attendance to walk a secured route inside the infield alongside Keselowski, all promoting wellness and general awareness for staying in-tune to their cholesterol levels. NEXLIZET should not be used in patients who have had a previous allergic reaction to ezetimibe. NEXLIZET and NEXLETOL can increase levels of uric acid in the blood which can lead to gout.

“Our partnership thus far with RFK has proven to be very successful in many facets, and we’re excited to again embark on a new journey with the team in 2024,” said Sheldon Koenig, CEO, Esperion. “As you can see, we have a robust marketing campaign lined up that highlights our various combined efforts on promoting everything from cholesterol awareness to various additional health awareness months. Our race schedule is exciting with tracks where RFK, Brad and Chris have excelled in the past, and we look forward to seeing the NEXLIZET and NEXLETOL Fords in victory lane very soon.”

Esperion 2024 Promotional Calendar
Feb. 2: National Wear Red Day
Feb. 6: American Heart Month video
Feb. 8: Prize pack giveaway
March 26-April 1: NASCAR.com race center takeover
April 2: Stress Awareness Month video
April 8: Buescher Appearance at ACC
May 1: Women’s Health Awareness video
May 15-21: NASCAR.com paint scheme preview takeover
June 3: Men’s Health Awareness video
July 9: Wellness Walk advance promotion
July 10-16: NASCAR.com paint scheme amplification content
July 13: Wellness Walk at Pocono Raceway
Sept. 1: Cholesterol Education Month video
Sept. 29: World Heart Day video
Oct. 2-8: NASCAR.com paint scheme amplification content
Oct. 6: In-car camera
Oct. 21: National Health Education Week video
Nov. 23: Family Health History Day video

About Esperion
Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
👍️0
FACT-MASTER FACT-MASTER 2 months ago
ESPR: Press Release January 23/24 re: share offering

https://finance.yahoo.com/news/esperion-announces-closing-public-offering-210000506.html
👍️0
FACT-MASTER FACT-MASTER 2 months ago
ESPR: Fact based article - Seeking Alpha

Excellent data based article and well composed, imo.

https://seekingalpha.com/article/4662729-esperion-sitting-on-potential-blockbuster-drug?utm_campaign=%7Clogin_now_link&utm_medium=email&utm_source=seeking_alpha
👍️0
glenn1919 glenn1919 2 months ago
ESPR...................................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
FACT-MASTER FACT-MASTER 3 months ago
Level II BID getting hammered into the close.

ASK is STACKED, at the moment.
👍️0
FACT-MASTER FACT-MASTER 3 months ago
ESPR : Ask gett'in annihilated here this afternoon!

January 11/24 3:22 ET
👍️0
FACT-MASTER FACT-MASTER 3 months ago
Ask on Level II looking heavy at the moment. (3:05 ET)

An announcement on a "dividend" might change this, imo, and of course, if the company can afford it.
👍️0
FACT-MASTER FACT-MASTER 3 months ago
ESPR: From the recent 10-Q

DSE Agreement Terms
On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was further amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (“DSE Territory”). DSE is responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.
Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive an additional regulatory milestone payment of either $200 million or $300 million upon inclusion of cardiovascular risk reduction data in the EU label, depending on the range of relative cardiovascular risk reduction in the CLEAR Outcomes study. Refer to Note 5 "Commitments and Contingencies" for further information. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company receives tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.

The agreement calls for both parties to participate in a Joint Collaboration Committee (the “DSE JCC”). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.
👍️0
FACT-MASTER FACT-MASTER 3 months ago
ESPR: NY Legal case settled

https://finance.yahoo.com/news/esperion-daiichi-sankyo-europe-announce-120000052.html

– Near term payment to Esperion of $100 million plus $25 million in calendar quarter following EMA’s expected decision on Type II(a) variation approval of NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet –

– Amendment also includes transfer of certain manufacturing and supply rights to DSE and expansion of collaboration in Europe and other territories –

ANN ARBOR, Mich. & MUNICH, January 03, 2024--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), announced today a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products.

DSE has agreed to pay Esperion $100 million in mid-January ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet. DSE will make an additional $25 million payment to Esperion in the calendar quarter immediately following EMA's decision on the pending application. The legal action pending in the United States District Court for the Southern District of New York will be dismissed.

The parties also agreed, as part of the resolution:

for Esperion to transition to DSE manufacturing and supply responsibilities in Europe and other territories, resulting in significant cost savings and efficiencies for both companies.

to expand their collaboration in Europe and other territories, to include the potential development and commercialization of a triple formulation product comprising bempedoic acid, ezetimibe and a statin, which could represent significant long-term value for the collaboration.

for DSE to now lead all regulatory communications with the EMA regarding the pending applications.

"We are pleased that this settlement creates value for Esperion today through cash payments and includes additional terms that will continue creating value for both companies going forward. Importantly, today’s settlement allows Esperion and DSE to focus on the business at hand – delivering life-saving drug therapies to millions with high cholesterol," said Sheldon Koenig, Esperion’s President and CEO. "Together, we are committed to making bempedoic acid a blockbuster franchise worldwide, based on the differentiating profiles of our products."

"This is a positive resolution for patients. We look forward to continuing to apply our combined strengths around the world to bring innovative pharmaceutical products to patients with cardiovascular disease, the greatest cause of death and disability globally," said Oliver Appelhans, Head of the Specialty Business Unit of Daiichi Sankyo Europe.

Since 2019, Esperion and DSE have worked together to bring bempedoic acid to the eligible patient population and unlock its potential for cardiovascular risk reduction. The partnership continues to grow, with DSE recently gaining approvals for bempedoic acid in the Netherlands, Slovakia, and Spain.
👍️0
glenn1919 glenn1919 3 months ago
ESPR........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
Gregg4 Gregg4 3 months ago
Been holding this three years now finally starting to move averages down starting at 20😂
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 months ago
$ESPR
https://x.com/hannahadad8890/status/1740326014075666477?s=61
👍️0
investorenquiry investorenquiry 3 months ago
https://www.sec.gov/Archives/edgar/data/1434868/000104746919000791/a2237755zex-10_16.htm
i want to read the exact language regrading the 300 mm dollar dispute???
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 3 months ago
$ESPR
https://x.com/hannahadad8890/status/1739968043525050426?s=61
👍️0
glenn1919 glenn1919 3 months ago
ESPR.......................................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
FACT-MASTER FACT-MASTER 3 months ago
ESPR: Pacermonitor link to case

https://www.pacermonitor.com/public/case/48290226/Esperion_Therapeutics,_Inc_v_Daiichi_Sankyo_Europe_GmbH

Latest entry here Thursday Dec.7/23:

"Minute Entry for proceedings held before Judge Edgardo Ramos: Pre-Motion Conference held on 12/7/2023 by telephone. Plaintiff's and Defendant's counsel present. Defendant is granted leave to file a motion to amend the answer with the following briefing scheduled: moving papers due January 4, 2024; opposition due January 25, 2024; and reply due February 1, 2024. For the reasons stated on the record, the Court will allow the deposition of Martin Fürle. (jar)"

Just my opinion, looks like extra time granted to the parties, - to reach a settlement, imo.
👍️0
FACT-MASTER FACT-MASTER 3 months ago
ESPR: Interesting read Nov.11/23

https://www.moomoo.com/community/feed/espr-stock-is-the-next-multi-bagger-1500-gains-expected-111393962590213
👍️0
billionareboysclub billionareboysclub 3 months ago
This is priming up really nice. Any new news aside from the ones posted here?
👍️0
glenn1919 glenn1919 3 months ago
ESPR........................................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESPR.................................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ESPR........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
Newbigtech Newbigtech 4 months ago
The Company ESPR has a Miracle Drug. Amgen, MERK, PFIZER all interested in making Money.
The company may get bought out, but $.4.00 a share is about $100.00 per share too low.
👍️0
Monksdream Monksdream 6 months ago
ESPR new 52 week low
👍️0
Paullee Paullee 6 months ago
more from seeking alpha

Takeover Targets
New: Today, 12:46 AM
Comments (23)
|
+ Follow
« Prev | Next »
10/04 Wall Street Rumors: Our Japan source says, Daiichi Sanko legal department is ready to negotiate with Esperion Therapeutics (ESPR) before the October 16th discovery date, on 10/03 more legal documents show at this time Daiichi has failed to present necessary documents to the court. We had the Case document 1:23-cv-02568 reviewed. It is obvious Daiichi Sankyo Europe $300 million milestone payment agreement was deliberately denied to use a tactic to negotiate a better offer, and more than likely an acquisition offer. Esperion has further milestone agreements between Daiichi and Otsuka totaling $1.5 billion. After careful review, Esperion is completely due the full $300 million milestone payment. Pointed out in the legal document noting the New England Journal of Medicine which reported 23% cardiovascular risk reduction, and entitles Esperion to the full $300 million payment based on the 20% marker agreement, further more Daiichi Sankyo Europe released news on 8/26:
New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease
- Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®? in Europe, provides a 20% reduction in the risk of total number of serious CV events in high-risk patients, complementing the previously reported 13%* reduction for the primary analysis.1,2
- A separate sub-analysis of the CLEAR Outcomes trial data shows patients with diabetes derive greater absolute benefit from bempedoic acid; furthermore, treatment does not increase HbA1c levels or the incidence of new-onset diabetes.3
- These findings support the benefits of long-term treatment with bempedoic acid to not only lower LDL-C but also reduce the risk for any – first and subsequent – CV events.
More details to come.
👍️0
Monksdream Monksdream 6 months ago
ESPR new 52 week low
👍️0
Paullee Paullee 6 months ago
from Seeking Alpha

Takeover Targets
New: Today, 7:57 AM
We expect a takeover offer for ESPR given our sources in Japan. WE RIETERATE 9/20/2023 UPDATE: Esperion Therapeutics (ESPR) dispute over $300 million milestone payment, On 9/14 Our source says it is rumored Daiichi Sankyo has been advised to pay Esperion. We have been forwarded this bit of information that says: ?????????????????????????????????????????????????????????????????????????
." We have concluded it would be in Daiichi Sankyo best interest to pay the requested $300 million milestone to Esperion Therapeutics, after careful review of the presented clinical data, the findings presented are favorable to Range of relative risk reduction of 20%, therefore as counsel for Daiichi Sankyo Europe we recommend immediate settlement ". On a separate note: We now have seen information for a several $200+ million loan offers presented to Esperion, these loan offers are non dilutive and have very favorable interest terms and are believed to be tied directly to the $300 million milestone. We are also aware of Form SC 13G filed by MILLENNIUM on 8/29/2023 that shows 2,100,000 shares were bought on the open market at an average $1.70 per share, MILLENNIUM now owns over 5% of Esperion, Institutions now own 87% of Esperion. We believe MILLENNIUM raised its stake this year based on the belief Daiichi Sankyo will settle this year, as does Bank of America analyst. The $300 million payment news would rally the stock price well above $4 a share. It is also very important to note on 8/26/2023 Daiichi Sankyo Europe wrote "Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®? in Europe, provides a 20% reduction in the risk of total number of serious CV events in high-risk patients, complementing the previously reported 13%* reduction for the primary analysis.1,2" Dr. Wolfgang Schiessl
Daiichi Sankyo Europe GmbH
PR & Portfolio Communication Lead, Specialty Medicines
+49 151 1714 7317. Daiichi Sankyo recent released earnings has reported 127% sales growth for Cholesterol drugs licensed from Esperion. We believe Daiichi is going to present Esperion with a BUYOUT offer rather than pay out $1.2 billion. By 2027 Esperion is expected to reach over 5 million patients being prescribed per year and this would generate over $20 billion yearly income. Daiichi Sankyo is now seeing higher prescription sales over PCSK9 inhibitors in Germany as reported by Esperion CEO on his presentation on 9/11/2023 shown on Esperion's website.
👍️0
Monksdream Monksdream 6 months ago
ESPR new 52 week low
👍️0
TJG TJG 9 months ago
Yesterday and today there have been 3 buys of over 200K shares at and around the $1.50 price range.... someone sees something that the market is not seeing. This morning at 9:37 224000 at 1.495 on the ASK of $1.50
👍️0
findit findit 9 months ago
ESPR - B of A Securities Upgrades Esperion Therapeutics to Buy, Raises Price Target to $4

June 15, 2023 6:21 AM |
👍️0
Awl416 Awl416 1 year ago
Good lord
👍️0
Gregg4 Gregg4 1 year ago
I’m long
👍️0
Paullee Paullee 1 year ago
jackpot
https://finance.yahoo.com/news/landmark-clear-outcomes-study-demonstrates-153000166.html
👍️0
glenn1919 glenn1919 1 year ago
ESPR....................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
susanmeadows susanmeadows 2 years ago
I like lamp.
👍️0
goforthebet goforthebet 2 years ago
anyone here buying that dip today??
👍️0
TheFinalCD TheFinalCD 2 years ago
$ESPR https://tweetdeck.twitter.com/
👍️0
Jaydixson1 Jaydixson1 3 years ago
I like espr
👍️0
keepemcloser keepemcloser 3 years ago
Back to 100 bucks !
👍️0
keepemcloser keepemcloser 3 years ago
And the slow march back to a buck begins.
👍️0
BuckeyeMike BuckeyeMike 3 years ago
If you get the weekly scrips please post or message me.

If you haven't listened to the Sept 14th Investors Conference Call, I think it's worth a listen. It's on the Esperion Website: https://morganstanley.webcasts.com/viewer/event.jsp?ei=1362617&tp_key=0d55b82feb

Scripts are outpacing all PCSK9i's compared to the launch of those drugs with virtually NO advertising AND during a Pandemic! PCSK9i's are a billion dollar drug and Nexletol and Nexlezit will make them obsolete before long. CEO Mayleben says as much on the Investor CC.

I think there's a good chance for atleast a 50% gain from these level prior to the end of the year.

Mark this post!

All the best

👍️0
jbeloc jbeloc 4 years ago
Keepmecloser and JC - It's good reading your posts. I just took a position here and wonder what you guys think is in store for us. I know that weekly scripts are going to be KEY data in moving this forward. I know from the AMRN board that Tucaman posts weekly scripts. Do you have any idea where he gets them? I would pay a service if I could get them for us.
👍️0
keepemcloser keepemcloser 4 years ago
Okeedohkee let’s try this again ok:
Looking forward to an excellent 4th quarter and good luck to all.
👍️0

Your Recent History

Delayed Upgrade Clock